Khouri Jessica M, Dabritz Haydee A, Payne Jessica R, Read Jennifer S, Chung Connie H
Infant Botulism Treatment and Prevention Program, Infectious Diseases Laboratories Division, Center for Laboratory Sciences, California Department of Public Health, Richmond, CA.
Infant Botulism Treatment and Prevention Program, Infectious Diseases Laboratories Division, Center for Laboratory Sciences, California Department of Public Health, Richmond, CA.
J Pediatr. 2025 Jan;276:114365. doi: 10.1016/j.jpeds.2024.114365. Epub 2024 Oct 18.
To characterize cases of outpatients with infant botulism (IB) in the US identified by the Infant Botulism Treatment and Prevention Program at the California Department of Public Health from 1976 through 2021.
Outpatient IB cases were defined as patients presenting with an illness consistent with the known paralyzing action of botulinum neurotoxin and with laboratory confirmation. Outpatient cases were distinguished from the majority of patients with IB by the atypical fact that they did not require hospitalization throughout the course of their illness.
Of the 4372 cases of IB identified by the Infant Botulism Treatment and Prevention Program over a 45-year period (1976-2021), 17 (0.4%) were outpatient cases. Most (11/17; 65%) cases occurred in California. The median age at disease onset was 20 weeks (range = 6 to 55 weeks). The most common symptom among cases was constipation (16/17; 94%). Most patients (16/17; 94%) had at least one cranial nerve palsy, manifested as decreased head control, ptosis, weak cry, or poor suck.
Outpatient IB occurs nationwide, although clinical diagnosis may be difficult because the severity of symptoms do not necessitate hospitalization or more comprehensive clinical intervention. Identification of outpatient cases requires an astute clinician and a capable, willing diagnostic testing laboratory. It is likely that more outpatient cases of IB are occurring than are presently recognized in infants mildly affected by this disease. Healthcare providers should consider the possibility of IB when presented with a previously well infant with failure to thrive, poor feeding, constipation, mild hypotonia, or cranial nerve palsy.
描述1976年至2021年期间,美国加利福尼亚州公共卫生部婴儿肉毒中毒治疗与预防项目所识别出的门诊婴儿肉毒中毒(IB)病例情况。
门诊IB病例定义为出现与已知肉毒杆菌神经毒素麻痹作用相符的疾病且经实验室确诊的患者。门诊病例与大多数IB患者的不同之处在于,其疾病过程中无需住院治疗这一非典型情况。
在婴儿肉毒中毒治疗与预防项目45年期间(1976 - 2021年)识别出的4372例IB病例中,17例(0.4%)为门诊病例。大多数(11/17;65%)病例发生在加利福尼亚州。发病时的中位年龄为20周(范围 = 6至55周)。病例中最常见的症状是便秘(16/17;94%)。大多数患者(16/17;94%)至少有一项颅神经麻痹,表现为头部控制能力下降、上睑下垂、哭声微弱或吸吮无力。
门诊IB在全国范围内均有发生,尽管临床诊断可能困难,因为症状的严重程度并不一定需要住院治疗或更全面的临床干预。识别门诊病例需要敏锐的临床医生和有能力且愿意进行诊断检测的实验室。受这种疾病轻度影响的婴儿中,可能存在比目前所认识到的更多的门诊IB病例。当面对生长发育不良、喂养困难、便秘、轻度肌张力减退或颅神经麻痹的既往健康婴儿时,医疗保健提供者应考虑婴儿肉毒中毒的可能性。